Replimune to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Replimune Group, a clinical stage biotechnology company, announced that CEO Philip Astley-Sparke will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 8:40 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Replimune Group, a clinical stage biotechnology company, announced that CEO Philip Astley-Sparke will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 8:40 AM ET. The event will take place virtually, and a webcast will be accessible on Replimune's website, with a replay available for 90 days post-conference. Replimune specializes in developing tumor-directed oncolytic immunotherapies using its proprietary RPx platform, aiming to enhance cancer treatment through innovative mechanisms.
Details
News Market Reaction – REPL
The recorded move for REPL in the trading session of this news was -2.39%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WOBURN, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference being held virtually on Friday, February 18, 2022 at 8:40 AM ET.
A simultaneous webcast will be available in the Investors section of Replimune’s website at www.replimune.com. A replay will be available for approximately 90 days following the conference.
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform has a unique dual local and systemic mechanism of action (MOA) consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment (TME) to ignite a strong and durable systemic response. This MOA is expected to be synergistic with most established and experimental cancer treatment modalities, and, with an attractive safety profile the RPx platform has the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com
Media Inquiries
Lissette Steele
Verge Scientific Communications
202.930.4762 x 409
lsteele@vergescientific.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.